Novelix Pharmaceuticals share news and announcements
BSE: 536565Healthcare ServicesSmall Cap
Last close ₹59.54down ₹3.19 (5.09%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹62.73.
52-week range of traded prices to 23 Oct 2026
₹45.03Low, 23 Oct 2025₹92.00High, 16 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹170 Cr2,861st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 46.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 11.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 8.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.09
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,524
Novelix Pharmaceuticals board meetings
132 filed, newest first. Page 1 of 3.
Aug 2026
29 Aug · Board meeting
25 Aug · Board meeting
Meeting on 29 Aug 2026: annual general meeting10 Aug · Board meeting
Meeting on 13 Aug 2026: quarterly results
Jul 2026
9 Jul · Board meeting
Jun 2026
4 Jun · Board meeting
1 Jun · Board meeting
Meeting on 4 Jun 2026: preferential issue of shares
May 2026
25 May · Board meeting
Meeting on 29 May 2026: audited results, preferential issue of shares and quarterly results
Mar 2026
30 Mar · Board meeting
Feb 2026
9 Feb · Board meeting
Meeting on 12 Feb 2026: quarterly results
Jan 2026
19 Jan · Board meeting
Meeting on 19 Jan 202619 Jan · Board meeting
Dec 2025
24 Dec · Board meeting
8 Dec · Board meeting
Meeting on 11 Dec 2025: preferential issue of shares
Nov 2025
10 Nov · Board meeting
Meeting on 13 Nov 2025: quarterly results
Oct 2025
23 Oct · Board meeting
Meeting on 23 Oct 202523 Oct · Board meeting
Aug 2025
7 Aug · Board meeting
Meeting on 14 Aug 2025: annual general meeting and quarterly results
Jun 2025
24 Jun · Board meeting
Meeting on 24 Jun 2025
May 2025
27 May · Board meeting
20 May · Board meeting
Meeting on 27 May 2025: audited results
Apr 2025
12 Apr · Board meeting
9 Apr · Board meeting
Meeting on 12 Apr 2025
Feb 2025
7 Feb · Board meeting
Meeting on 12 Feb 2025: quarterly results
Nov 2024
11 Nov · Board meeting
Meeting on 13 Nov 2024: quarterly results
Oct 2024
21 Oct · Board meeting
7 Oct · Board meeting
Meeting on 21 Oct 2024: increase in authorised capital and issue of warrants
Sep 2024
2 Sep · Board meeting
Aug 2024
23 Aug · Board meeting
Meeting on 2 Sep 2024
Jul 2024
31 Jul · Board meeting
Meeting on 8 Aug 2024: quarterly results
Jun 2024
25 Jun · Board meeting